We prospectively examined influence of androgen deprivation therapy (ADT) on lipid and glucose metabolisms in Japanese patients with prostate cancer.
Patients with prostate cancer who were hormone-naive and scheduled to receive long-term ADT were recruited between 2011 and 2013.
Body weight, abdominal circumference and blood testing associated with lipid and glucose metabolism were recorded every 3 months during 1 year of ADT. Computed tomography (CT) was performed to measure areas of subcutaneous and visceral fat before and after 1 year of ADT. ADT was limited to a luteinizing hormone-releasing hormone (LHRH) agonist with or without bicalutamide.
Of 218 patients registered, data were available from 177 patients who completed 1 year of ADT. Of these, CT was performed before and after 1 year of ADT in 88 patients. Median age was 75 years (range, 49-85 years). Median PSA before ADT was 16. 7 ng ml(-1) (range, 0. 3-3316). Clinical stage was B (54. 2%), C (23. 2%) and D (20. 9%). Mean increases in body weight and abdominal circumference after 1 year of ADT were 2. 9 and 3. 0%, respectively. Mean increases in total, low-density lipoprotein and high-density lipoprotein cholesterol and triglycerides were 10. 6, 14. 3, 7. 8 and 16. 2%, respectively. Mean increases in fasting blood sugar and hemoglobin A1c (HbA1c) were 3. 9 and 2. 7%, respectively. Lipid alterations were noted in patients without comorbidities, whereas changes in HbA1c were noted in patients with diabetes mellitus at baseline. These lipid and glucose alterations were prominent in the early ADT period. Both visceral and subcutaneous fat, as measured by CT, increased by >20%. The increase in subcutaneous fat was significantly greater than that in visceral fat (P=0. 028).
One year of ADT significantly changed lipid and glucose metabolism in Japanese patients with prostate cancer. Patient characteristics or comorbidities at baseline may be associated with ADT-induced metabolic changes. Prostate Cancer and Prostatic Diseases advance online publication, 27 October 2015; doi:10. 1038/pcan. 2015. 50.
Prostate cancer and prostatic diseases. 2015 Oct 27 [Epub ahead of print]
K Mitsuzuka, A Kyan, T Sato, K Orikasa, M Miyazato, H Aoki, N Kakoi, S Narita, T Koie, T Namima, S Toyoda, Y Fukushi, T Habuchi, C Ohyama, Y Arai, Tohoku Evidence-Based Medicine Study Group , Michinoku Urological Cancer Study Group
Department of Urology, Tohoku University School of Medicine, Sendai, Japan. , Department of Urology, Shirakawa Kosei General Hospital, Shirakawa, Japan. , Department of Urology, Shirakawa Kosei General Hospital, Shirakawa, Japan. , Department of Urology, Kesen-numa City Hospital, Kesen-numa, Japan. , Department of Urology, Ryukyu University, Nishihara, Japan. , Department of Urology, Sendai City Hospital, Sendai, Japan. , Department of Urology, Miyagi Cancer Center, Natori, Japan. , Department of Urology, Akita University School of Medicine, Akita, Japan. , Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan. , Department of Urology, Tohoku Rosai Hospital, Sendai, Japan. , Department of Urology, Sendai Jin Hinyokika Clinic, Sendai, Japan. , Department of Urology, Sendai Yanagyu Clinic, Sendai, Japan. , Department of Urology, Akita University School of Medicine, Akita, Japan. , Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan. , Department of Urology, Tohoku University School of Medicine, Sendai, Japan.